Navigation Links
Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
Date:6/22/2009

Adaptive trials leader and CDRH regulators join to create Bayesian trial design and analysis software standard

CAMBRIDGE, Mass., June 22 /PRNewswire/ -- Cytel Inc., a leading provider of biostatistical software and clinical trial design services, today announced the signing of a Cooperative Research And Development Agreement (CRADA) with the Center for Devices and Radiological Health (CDRH), a division of the United States Food and Drug Administration (FDA).

The agreement acknowledges that despite the CDRH's encouragement of clinical study sponsors to employ Bayesian-based device trials, no validated, easy-to-use design or analysis software has emerged. The goal of the CDRH collaboration with Cytel is to eliminate the productivity-sapping cycles of developing and validating ad-hoc methodologies with a reliable and easily-learned standard software package for both trial sponsors and regulators.

Gerry W. Gray, Ph.D., is the Principal Investigator for the FDA. Nitin Patel, Ph.D., Cytel Co-Founder, Chairman, and Chief Technology Officer, will lead the development effort as Cytel Principal Investigator.

Dr. Patel commented, "We are honored that CDRH chose Cytel as their partner for developing validated, documented, and commercially available Bayesian software. The CRADA is completely aligned with our vision of implementing innovative device and drug development approaches by combining high-quality software and knowledge-intensive services. Creation of these best-in-class Bayesian tools is a crucial initiative in our efforts to help the clinical development community to reduce time-to-market, cut costs, and improve portfolio returns."

The CRADA Research Plan Abstract

The Center for Devices and Radiological Health (CDRH) at the FDA encourages sponsors to use innovative Bayesian designs for clinical trials involving device products. The Bayesian approach provides a natural way to combine prior evidence with current data. Moreover for devices, good prior information often exists, as for example in studies of previous generations of the same device. At the present time the software tools that are needed for designing and analyzing Bayesian clinical trials are not available in any validated, commercially viable, easy to use software package. Thus, execution of Bayesian clinical trials requires considerable expertise in both Bayesian methodology and in computer programming.

Further, CDRH statisticians usually need to write special programs to verify the operating characteristics of each Bayesian submission separately. This is an inhibiting factor and puts considerable burden on sponsors in carrying out the simulations that are submitted to CDRH and on CDRH statisticians in validating what is submitted.

About Cytel

Cytel Inc. is a leading provider of specialized statistical software and clinical trial services for the biopharmaceutical, medical device, academic and government research markets.

Cytel pioneered the statistical and computational science of adaptive clinical trials and has designed more validated adaptive trials than any other service provider. Cytel serves trial sponsors with innovative tools, training and consultation to increase the return on investment in clinical development.


'/>"/>
SOURCE Cytel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
3. Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug
4. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
5. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
6. Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
7. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
8. Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
9. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
10. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
11. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):